Literature DB >> 8554545

Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L.

D Jean1, J Hermann, F Rodrigues-Lima, M Barel, M Balbo, R Frade.   

Abstract

We previously identified, on normal or tumour cells, two membrane proteinases, p57 and p65, that cleave human C3, the third component of complement, thus regulating C3's biological properties. Whereas p57 was purified from human erythrocytes, p65 was identified using polyclonal anti-p57 antibodies on a human melanoma cell line resistant to complement lysis. Analysis of cell distribution of C3-cleaving proteinases established that DSm, a murine melanoma cell line, expressed a C3-cleaving proteinase distinct from p57 and p65 proteinases. Thus we purified the C3-cleaving proteinase solubilized from membranes of DSm cells. The purified proteinase, termed 'p39' on the basis of its molecular mass of 39 kDa, was identified, using specific proteinase inhibitors, as a cysteine proteinase. Anti-p39 antibodies, prepared against highly purified p39, localized the p39 C3-cleaving proteinase mainly at the cell surface and demonstrated that p39 is also secreted. Anti-p39 antibodies inhibited solubilized C3-cleaving activity. Preincubation of DSm cells with anti-p39 F(ab')2 fragments increased up to 60% complement cell susceptibility. Amino acid analysis of N-terminal and three other regions of p39 demonstrated that this C3-cleaving proteinase carries 100% identity within four regions of procathepsin L. This is the first demonstration that a melanoma cell line expresses on its surface and secretes a p39 C3-cleaving cysteine proteinase that shares sequence identities with procathepsin L. Thus the p39 cysteine proteinase represents a new member of the C3-cleaving proteinase family associated with, and/or expressed on, the cell surface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554545      PMCID: PMC1136207          DOI: 10.1042/bj3120961

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Molecular biology and chemistry of the alternative pathway of complement.

Authors:  H J Müller-Eberhard; R D Schreiber
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

3.  A one-step purification of membrane proteins using a high efficiency immunomatrix.

Authors:  C Schneider; R A Newman; D R Sutherland; U Asser; M F Greaves
Journal:  J Biol Chem       Date:  1982-09-25       Impact factor: 5.157

4.  Behavior of soluble human 125I-labeled C3b, the third component of complement, after binding to human cells.

Authors:  C Charriaut; M Barel; R Frade
Journal:  Eur J Immunol       Date:  1982-04       Impact factor: 5.532

5.  The physiological breakdown of the third component of human complement.

Authors:  R A Harrison; P J Lachmann
Journal:  Mol Immunol       Date:  1980-01       Impact factor: 4.407

6.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

7.  gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).

Authors:  R Frade; B L Myones; M Barel; L Krikorian; C Charriaut; G D Ross
Journal:  Eur J Immunol       Date:  1985-12       Impact factor: 5.532

8.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

9.  Human erythrocyte ankyrin, a cytoskeleton component, generates the p57 membrane proteinase which cleaves C3, the third component of complement.

Authors:  J Hermann; M Barel; R Frade
Journal:  Biochem Biophys Res Commun       Date:  1994-10-28       Impact factor: 3.575

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Cathepsin L increased level upon Ras mutants expression: the role of p38 and p44/42 MAPK signaling pathways.

Authors:  Lorena Urbanelli; Francesco Trivelli; Luisa Ercolani; Eleonora Sementino; Alessandro Magini; Brunella Tancini; Raffaella Franceschini; Carla Emiliani
Journal:  Mol Cell Biochem       Date:  2010-06-04       Impact factor: 3.396

4.  Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity.

Authors:  Didier Jean; Nathalie Guillaume; Raymond Frade
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

5.  Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells.

Authors:  Nathalie Guillaume-Rousselet; Didier Jean; Raymond Frade
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

Review 6.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

Review 7.  Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.

Authors:  Janko Kos; Ana Mitrović; Milica Perišić Nanut; Anja Pišlar
Journal:  FEBS Open Bio       Date:  2022-02-03       Impact factor: 2.693

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.